patient subgroup...
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression kidney transplant recipients obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline solid cancer solid organ transplant recipients subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
vaccines - versus vaccines - for COVID-19 prophylaxis (excluding children)
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 deaths 0.12 [0.06, 0.24]< 1 85% 4 studies (-/4) 100.0 % low not evaluable high crucial - deaths (time to event analysis only) 0.22 [0.17, 0.28]< 1 0% 1 study (-/1) 100.0 % NA not evaluable crucial - hospitalization or death 0.21 [0.12, 0.37]< 1 0% 2 studies (-/2) 100.0 % NA not evaluable crucial - confirmed COVID (any severity) 0.34 [0.27, 0.42]< 1 99% 17 studies (3/14) 100.0 % NA low important - hospitalization 0.21 [0.07, 0.61]< 1 98% 9 studies (-/9) 99.8 % NA not evaluable important - symptomatic Covid-19 0.42 [0.36, 0.51]< 1 93% 7 studies (2/5) 100.0 % NA not evaluable important - ICU admission 0.33 [0.08, 1.36]< 1 0% 1 study (-/1) 93.7 % NA not evaluable non important - severe COVID-19 (FDA definition) 0.25 [0.01, 5.50]< 1 0% 1 study (1/-) 80.8 % NA not evaluable non important - severe COVID-19 occurrence 0.13 [0.06, 0.31]< 1 95% 6 studies (1/5) 100.0 % NA not evaluable non important - 00 adverse events 0.98 [0.76, 1.27]< 1 8% 2 studies (2/-) 55.2 % NA not evaluable non important - arrhythmia 1.99 [0.07, 59.22]< 1 0% 1 study (1/-) 34.8 % NA not evaluable non important - hypertension 0.50 [0.02, 14.80]< 1 0% 1 study (1/-) 65.5 % NA not evaluable non important - intracranial hemorrhage 0.81 [0.11, 5.77]< 1 0% 4 studies (3/1) 58.3 % NA not evaluable non important - ischemic stroke 0.90 [0.14, 5.94]< 1 0% 4 studies (3/1) 54.3 % NA not evaluable non important - Myocardial infarction 0.76 [0.25, 2.31]< 1 0% 6 studies (5/1) 68.3 % low not evaluable high non important - pulmonary embolism 0.50 [0.10, 2.60]< 1 0% 5 studies (4/1) 79.3 % NA not evaluable non important - serious adverse events (SAE), any 1.53 [0.25, 9.36]< 1 0% 1 study (1/-) 32.3 % NA not evaluable non important - stroke (non-specific, hemorrhagic, and ischemic) 0.99 [0.06, 15.88]< 1 0% 1 study (1/-) 50.2 % NA not evaluable non important - venous thromboembolism 0.94 [0.12, 7.29]< 1 0% 3 studies (3/-) 52.5 % NA not evaluable non important - 00 cerebral venous sinus thrombosis (CVST) 0.50 [0.02, 14.80]< 1 0% 1 study (1/-) 65.5 % NA not evaluable important - appendicitis 3.97 [0.18, 88.14]< 1 0% 1 study (1/-) 19.4 % NA not evaluable non important -
LoD: level of statistical demonstration:
